Alliances Up In Japan, And A Shift To Overseas Markets
This article was originally published in The Pink Sheet Daily
Japanese pharma’s appetite for licensing deals exploded in 2011, as did its appetite for foreign marketing rights.
You may also be interested in...
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?